Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares OutstandingShares Outstanding
Ratios

Tandem Diabetes Care (TNDM) Long-Term Debt Issuances (2013 - 2026)

Tandem Diabetes Care posted quarterly Long-Term Debt Issuances of $291.2 million for Q1 2026, down 5.11% on a QoQ basis from $306.8 million in Q1 2024.

Tandem Diabetes Care (TNDM) has 4 years of Long-Term Debt Issuances data on file, last reported at $291.2 million in Q1 2026.

  • For the quarter ending Q1 2026, Long-Term Debt Issuances changed N/A year-over-year to $291.2 million; the trailing twelve-month figure through Mar 2026 stood at $291.2 million (changed N/A YoY), and the FY2024 full-year result was $306.8 million, changed N/A from the prior year.
  • Long-Term Debt Issuances for Q1 2026 stood at $291.2 million, down from $306.8 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $306.8 million in Q1 2024 and bottomed at $291.2 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 19.86 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 11.71 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 1.15 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Tandem Diabetes Care 1.31 Bn 739.55 Mn 136.79 Mn 291.16 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 291.16 Mn
Mar 31, 2026 291.16 Mn
Mar 31, 2024 306.85 Mn
Mar 31, 2024 306.85 Mn
Dec 31, 2016 35.00 Mn
Dec 31, 2016 35.00 Mn
Mar 31, 2016 14.99 Mn
Mar 31, 2016 14.99 Mn
Dec 31, 2013 -504.00
Dec 31, 2013 -504.00
Sep 30, 2013 -374,550.00
Sep 30, 2013 -374,550.00
Jun 30, 2013 374,549.00
Jun 30, 2013 374,549.00
Mar 31, 2013 28.87 Mn
Mar 31, 2013 28.87 Mn